


RESULTS


- 50 patients
- 25♂, 25♀
- Age: 59,24 mean (5,9 SD) range: 47,34-70,30
- Age of acute infection: mean 28,67 mnt
range: 0,2-120 mnt
- Date of acute infection: 1938-1963

Worsening: years after acute infection




Timing of treatment

10,8 years (mean) after worsening



- homogeneous ($p < 0,05$)
 - Age
 - Age of acute infection
 - Fatigue (FSS)
 - Pain (VAS)


Quality of life (SF36): health and pain




FATIGUE

FSS


$p=0,039$




Pain




6 MWT



6 MWT Ig




6 MWT placebo



MUSCULAR STRENGTH

- Both MRC and dynamometer after IGIV treatment did not show variation respect to the placebo group.



DISCUSSION

- Treated patients show a statistically relevant ($p=0,039$) reduction of FATIGUE (FSS) respect to placebo group.
- PAIN decrease in treated patients failed to reach statistical relevance but shows a trend.
- QUALITY OF LIFE increases in treated patients.

MUSCULAR STRENGTH ?????



```
graph TD; A[MUSCULAR STRENGTH ?????] --> B[REAL CLINICAL RESPONSE]; A --> C[CLINICAL BIAS];
```

REAL CLINICAL RESPONSE

CLINICAL BIAS

PREDICTORS

PREDICTORS

- Timing of treatment after worsening?
- Severity of fatigue?
- Severity of acute infection?
- Severity of worsening?

Millo Martini
Bruno Danzi
Elisa Dall'Ora
Monica Ferlisi
Fabiana Pimazzoni
Emma Frasson
Gianfranco Di Gennaro
Elisabetta Zanolin

thank for your attention